China Proposes Rolling Submissions For Innovative New Drugs
Also Priority Reviews For Breakthrough Products
A revised regulatory approach in China will include rolling data submissions among new incentives for the development of innovative new drugs in a bid to further accelerate the approval of such products.
You may also be interested in...
China’s new Five-Year Plan for drug quality aims to address hurdles in clinical study ethics committee review while leaving out other restrictions including genetic material export and substandard clinical sites.
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.
Only drugs awarded high points under a government-designated scoring method will benefit most from a new pricing scheme in China. The criteria include the products’ innovativeness in terms of pharmaceutical sciences, the clinical value for patients and clinical evidence from clinical studies.